CNN2 · Western blot design guide

CNN2 Western Blot Planning Guide

Plan a CNN2 Western blot around the catalog-observed 33.7 kDa band, image-backed A08680-2 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for CNN2 (CNN2): expected band 33.7 kDa, antibody A08680-2, and guide-derived SDS-PAGE protocol steps
CNN2 Western blot protocol sheet — expected band 33.7 kDa, antibody A08680-2, controls and PMC citations. Open the full CNN2 WB guide →

CNN2 Western Blot Experimental Design Guide

Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 33.7 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Lung
Negative control ⓘ Bone marrow
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 33.7 kDa
ⓘ Localization Not reported
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human
Section 1

Real Curated CNN2 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateLung
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA08680-2 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected CNN2 Western Blot Band Size?

Use the product-observed 33.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
33.7 kDaMatches the authoritative product WB observation.
33.7 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected CNN2 appearancePlan around 33.7 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band33.7 kDa; use this as the primary experimental expectation.
Calculated mass33.7 kDa from UniProt Q99439; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A08680-2.
Why is my band missing or off?
SituationLikely causeNext action
33.7 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for CNN2 Western blot

🧪Use Lung as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Lung (Medium)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for CNN2

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Lung Reported tissue cells Medium Protein (HPA) HPA →
Lymph node Reported tissue cells Medium Protein (HPA) HPA →
Tonsil Reported tissue cells Medium Protein (HPA) HPA →
Breast Reported tissue cells Low Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Bone marrow Reported tissue cells Not detected Protein (HPA) HPA →
Bronchus Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced CNN2 Western Blot Tips

Deeper troubleshooting and optimisation questions for CNN2, answered from its protein features.

Which band should guide the blot?
Use 33.7 kDa, the observation attached to the authoritative A08680-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 33.7 kDa expectation.
Which positive control should I start with?
Start with Lung, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CNN2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A08680-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

CNN2 Western Blot Reagents

Human-reactive CNN2 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for CNN2 using A08680-2; observed band 33.7 kDa
Anti-Calponin 2/CNN2 Antibody Picoband®
Cat # A08680-2

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt Q99439
  2. Human Protein Atlas — CNN2
  3. A08680-2 product record
  4. PMC5765741 — Lentivirus-mediated shRNA Targeting CNN2 Inhibits Hepatocarcinoma in Vitro and in Vivo (International journal of medical sciences, 2018)
  5. PMC10185810 — CNN2 silencing inhibits colorectal cancer development through promoting ubiquitination of EGR1 (Life science alliance, 2023)